First-line antihypertensive treatment in patients with pre-diabetes: Rationale, design and baseline results of the ADaPT investigation
- Once-Weekly BYDUREON(tm) Provided Greater Glucose Control, Weight Loss and Lower Risk of Hypoglycemia Compared to Once- or Twice-Daily Levemir(r) in Type 2 Diabetes. // Biomedical Market Newsletter;6/18/2012, Vol. 21, p1
The article informs that Amylin Pharmaceuticals Inc. and Alkermes PLC has released the results from its clinical trials of BYDUREON and Levemir for the treatment of type 2 diabetes. A comparative study revealed that BYDUREON is a once weekly treatment which is more efficient in controlling...
- BYDUREON(tm) Was Associated with Significant and Sustained Glycemic Control at Four Years. // Biomedical Market Newsletter;6/18/2012, Vol. 21, p1
The article informs that Amylin Pharmaceuticals Inc. and Alkermes PLC has released the results from its clinical trial of BYDUREON for the treatment of type 2 diabetes. It mentions that the efficacy of once-weekly treatment BYDUREON and twice-daily BYETTA was compared which revealed that...
- BYETTA(r) Provided Greater Glycemic Durability and Overall Glycemic Control than Amaryl(r) in Patients with Type 2 Diabetes. // Biomedical Market Newsletter;6/18/2012, Vol. 21, p1
The article informs that Amylin Pharmaceuticals Inc. has released the results from its comparative clinical trial of BYETTA and Amaryl for the treatment of type 2 diabetes. It mentions that BYETTA resulted in glycemic durability, weight loss and reduced risk of hypoglycemia. It further informs...
- A Novel Antihypertensive Effect of Exenatide, a GLP-1 Agonist. Dandona, Paresh; Chaudhuri, Ajay; Dhindsa, Sandip // American Journal of Hypertension;Mar2010, Vol. 23 Issue 3, p228
In this article the author comments on the anti-hypertensive efficacy of the glucan-like peptide-1 (GLP-1) exenatide for the treatment of hypertension and prevention from hyperglycemia. The author is particular on the consistent reduction of systolic blood pressure among 2,171 patients with type...
- Patiromer effective for drug-associated hyperkalaemia. // Reactions Weekly;Aug2015, Vol. 1562 Issue 1, p10
The article discusses research published in the July 14, 2015 issue of "The Journal of the American Medical Association" that investigated the efficacy of patirometer in patients with type 2 diabetes mellitus receiving renin-angiotensin-aldosterone system (RAAS) inhibitors.
- Finding ACCORD in the Management of Type 2 Diabetes? // Critical Care Alert;May2010 Pharmacology, p1
The article offers information on the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial which is intended to complement the management of type 2 diabetes.
- Trend of clinical drug trials in type 2 diabetes mellitus over last decade. Parikh, Rakesh; Pandia, Kirti; Goyal, Mahesh; Sharma, Meenakshi; Dolima, M. S. // Perspectives in Clinical Research;2011, Vol. 2 Issue 2, p64
Background: Type 2 diabetes mellitus (Type 2 DM) has been recognized as the recent pandemic; India and China competing each other for the title--"Diabetes Capital of the World." A number of new drugs have been recently available and has lead to a boom in the clinical drug trial industry. We...
- Combination Therapy Clinical Trials. // Pharmacy Today;Sep2011 Supplement, p4
The article focuses on the clinical trials that evaluate the efficacy and safety of dipeptidyl-peptidase-4 (DDP-4) inhibitor called Tradjenta as an add-on therapy to metformin and pioglitazone in patients with type 2 diabetes with inadequate glycemic control.
- Comparative efficacy of humalog mix 75/25 with human Insulin. Wal, Pranay; Wal, Ankita; Srivastava, Shivangi; Srivastava, Abhinav; Pandey, Umeshwar; Jain, Tarun; Rai, Awani K. // Journal of Pharmaceutical Sciences & Research;2010, Vol. 2 Issue 5, p302
The study is designed to compare the postprandial glucodynamic profile of humalog mix 75/25, a new premixed insulin analogue containing 75% neutral protamine lispro and 25% insulin lispro with that of human insulin 70/30 in patients with type 2 diabetes mellitus. Insulin lispro mix 75/25 is the...